Riskpilot← Back to searchSign inGet full accessCAMPUS Pharma AB
ABActiveOrg 5565340287Karl Gustavsgatan 1 AWholesale of pharmaceutical and medical goods · NACE 4646Est. 199620-49 employees
Revenue 2024
SEK 262,5M
+25% vs 2023
EBITDA margin
17.3%
+102% vs 2023
Equity ratio
43.4%
Financial strength
Net profit 2024
SEK 23,6M
+632% vs 2023
| Revenue | SEK 262,5M | +25% |
| EBITDA | SEK 45,4M | +102% |
| Net profit | SEK 23,6M | +632% |
| Total assets | SEK 112,2M | -16% |
| Equity | SEK 48,7M | -22% |
| Employees | — | — |
Legal name
CAMPUS Pharma AB
Org number
5565340287
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
13 september 1996
Share capital
SEK 100 000
Employees
20-49
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas av en av Barallobre Gordon, Carlos Tarride, Francois-Xavier i förening med Stenström, Per Anders Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget skall ha till föremål för sin verksamhet att tillverka och försälja läkemedel, kemiska produkter, naturmedel och medicinska utensilier, förvalta aktier samt idka därmed förenlig verksamhet.
Address
Karl Gustavsgatan 1 A
Phone
+4631205020
Email
anders.stenstrom@campuspharma.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | 109 541 | 139 593 | 145 142 | 168 353 | 175 079 | 209 853 | 262 527 |
| Staff expenses | — | — | — | — | — | — | — | — | — | −62 924 |
| EBITDA | 9 169 | 4 771 | 2 786 | 1 358 | 6 161 | 10 547 | 19 981 | 17 429 | 22 422 | 45 388 |
| Depreciation & amort. | −346 | −367 | −369 | −400 | −11 157 | −25 943 | −25 773 | −25 699 | −26 171 | −15 719 |
| EBIT | 8 823 | 4 404 | 2 417 | 958 | −4 996 | −15 396 | −5 792 | −8 270 | −3 749 | 29 669 |
| Net financials | −53 | −28 | −76 | −25 | −1 060 | −1 771 | −1 580 | −1 196 | −1 342 | −530 |
| Profit before tax | 6 719 | 4 157 | 5 342 | −66 | −5 482 | −10 787 | −5 017 | −6 455 | −5 090 | 29 139 |
| Tax | −1 554 | −1 012 | −1 522 | −360 | 811 | 2 174 | 897 | 186 | 656 | −5 571 |
| Net profit | 5 165 | 3 145 | 3 820 | −426 | −4 671 | −8 613 | −4 120 | −6 269 | −4 434 | 23 568 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 55 150 | 53 841 | 57 307 | 67 042 | 185 159 | 166 252 | 154 205 | 119 402 | 133 289 | 112 205 |
| Equity | 27 632 | 26 778 | 26 598 | 25 272 | 87 239 | 78 626 | 74 506 | 68 237 | 62 563 | 48 731 |
| Long-term debt | 0 | 0 | 1 185 | 0 | 55 814 | 0 | 0 | 0 | 0 | — |
| Short-term debt | 13 416 | 12 743 | 18 204 | 29 450 | 30 360 | 82 261 | 76 688 | 51 165 | 69 720 | 63 411 |
| Total debt | 13 416 | 12 743 | 19 389 | 29 450 | 86 174 | 82 261 | 76 688 | 51 165 | 69 720 | 63 411 |
EBITDA margin
17.3%
This company
15.8%
Market median
+9% vs market
20152024
Equity ratio
43.4%
This company
38.2%
Market median
+14% vs market
20152024
Return on equity
48.4%
This company
18.4%
Market median
+163% vs market
20152024
Net profit margin
9.0%
This company
8.1%
Market median
+11% vs market
20152024
Asset turnover
2.34×
This company
1.12×
Market median
+109% vs market
20152024
Debt / equity
1.30×
This company
0.62×
Market median
-110% vs market
20152024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via Bolagsverket / SCB · Period 2015-01-01 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
PA Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
FD Chief Auditor | Chief Auditor | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Chairman | 2025 | — | — | |
| Board of Directors | 2022 | — | — | |
| Deputy Board Member | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2022 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
ITF SA - SPAIN | Company | 60.0% | 60.0% | 2025 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
ITF SA - SPAIN
CAMPUS Pharma AB (this company)Board members of CAMPUS Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Per Anders Stenström | Chief Executive Officer | 0 companies |
| Filip David Larsson | Chief Auditor | 0 companies |
| Francois-Xavier Tarride | Chairman | 0 companies |
| Lourdes Maria Fraguas Gadea | Board of Directors | 0 companies |
| Therese Wolo Joxelius Kanga | Deputy Board Member | 0 companies |
| Edgard Marie Marcel Bertrand | Board of Directors | 0 companies |
| Carlos Barallobre Gordon | Board of Directors | 0 companies |
| Francesco De Santis | Chairman | 0 companies |
| Peter Joxelius | Board of Directors | 0 companies |
| Alessandro Micheli | Board of Directors | 0 companies |